background
sever
fever
thrombocytopenia
syndrom
sft
emerg
infecti
diseas
china
japan
korea
character
high
fever
thrombocytopenia
high
mortal
hypothes
cytokin
storm
play
import
role
pathophysiolog
sft
howev
limit
data
publish
detail
kinet
viral
load
cytokin
profil
throughout
cours
diseas
object
investig
pattern
chang
cytokin
viral
load
sft
patient
studi
design
admiss
period
patient
rna
extract
plasma
quantifi
revers
transcript
polymeras
chain
reaction
addit
cytokin
bead
array
perform
cytokin
chemokin
select
test
result
median
time
admiss
neg
convers
sft
viremia
day
censor
patient
found
neg
viral
load
discharg
median
durat
viral
shed
day
ci
interferon
ifn
interleukin
il
protein
ip
concentr
significantli
increas
earli
cours
diseas
decreas
hospit
stay
howev
concentr
tumor
necrosi
regul
activ
normal
tcell
express
secret
rant
vascular
endotheli
growth
factor
vegf
increas
late
cours
diseas
initi
level
hospit
day
significantli
correl
initi
viral
load
r
p
sever
fever
thrombocytopenia
syndrom
sft
emerg
infecti
viral
diseas
china
japan
korea
sft
viru
sftsv
belong
genu
phleboviru
famili
bunyaviru
first
identifi
group
chines
medic
research
major
clinic
sign
symptom
sft
fever
abdomin
pain
vomit
nausea
thrombocytopenia
leukocytopenia
multipl
organ
failur
sometim
occur
mortal
rate
previou
studi
use
pathogen
mous
model
sft
report
viral
rna
detect
enrich
primarili
spleen
acut
phase
diseas
studi
also
suggest
viru
attach
surfac
platelet
detect
cytosol
macrophag
macrophag
may
phagocytos
sftsvattach
platelet
knockout
mous
model
dendrit
cell
megakaryocyt
monocyt
macrophag
neutrophil
endotheli
cell
target
viru
rather
reticular
cell
lymphoid
tissu
intestin
spleen
major
target
cell
human
howev
pathogenesi
diseas
poorli
understood
due
insuffici
data
hypothes
cytokin
storm
play
import
role
pathophysiolog
sft
profil
concern
cours
diseas
reason
investig
pattern
chang
cytokin
viral
load
sft
patient
cours
diseas
juli
octob
prospect
enrol
patient
sft
asan
medic
center
sftsv
infect
confirm
use
posit
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
detect
viral
rna
plasma
sampl
obtain
patient
hospit
period
place
edtatr
collect
tube
sampl
immedi
frozen
analysi
plasma
sampl
healthi
volunt
analyz
healthi
control
cytokin
analysi
studi
protocol
approv
institut
review
board
asan
medic
center
viral
load
sftsv
measur
use
onestep
multiplex
realtim
rtpcr
detect
rna
extract
plasma
sampl
use
qiagen
rneasi
mini
kit
qiagen
hilden
germani
detect
sftsv
segment
gene
quantifi
human
beta
actin
gene
use
intern
control
sequenc
primer
probe
use
studi
follow
measur
cytokin
chemokin
level
plasma
sampl
patient
healthi
volunt
simultan
cytometr
bead
array
base
microspher
detect
cytokin
chemokin
accord
manufactur
instruct
bd
bioscienc
san
jose
ca
measur
granulocyt
colonystimul
factor
gcsf
granulocyt
macrophag
colonystimul
factor
gmcsf
interferon
ifn
tumor
necrosi
interleukin
il
monocyt
chemotact
protein
mcp
macrophag
inflammatori
protein
mip
regul
activ
normal
tcell
express
secret
rant
protein
ip
vascular
endotheli
growth
factor
vegf
data
acquir
use
fac
canto
ii
flow
cytomet
facsdiva
softwar
bd
bioscienc
san
jose
ca
flowjo
softwar
flowjo
llc
ashland
statist
analys
perform
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
spss
window
softwar
packag
version
spss
inc
chicago
il
classifi
diseas
progress
follow
hospit
day
statist
differ
among
period
analyz
use
kruskalw
test
viral
load
survivor
nonsurvivor
compar
use
mannwhitney
u
test
spearman
test
use
calcul
correl
coeffici
cytokinechemokin
level
viral
rna
load
median
time
admiss
neg
convers
viremia
analyz
use
kaplanmei
surviv
analysi
test
signific
twotail
p
valu
less
consid
statist
signific
total
patient
sft
confirm
sftsvspecif
rtpcr
test
plasma
specimen
enrol
studi
among
patient
eight
men
mean
age
standard
deviat
group
year
underli
diseas
present
three
sft
patient
four
case
occur
spring
summer
seven
case
occur
fall
patient
fever
thrombocytopenia
seven
patient
show
alter
mental
statu
ten
patient
surviv
one
die
cours
hospit
detail
clinic
characterist
patient
shown
tabl
mean
age
standard
deviat
control
subject
year
male
detail
viral
load
kinet
patient
shown
fig
initi
viral
load
measur
day
admiss
plasma
specimen
patient
includ
nine
survivor
one
nonsurvivor
nine
survivor
mean
initi
viral
load
log
viral
rna
level
gradual
decreas
cours
diseas
howev
initi
viral
load
log
increas
time
death
nonsurvivor
supplementari
fig
signific
differ
plasma
viral
rna
level
admiss
survivor
nonsurvivor
p
supplementari
fig
median
time
neg
convers
rtpcr
result
sftsv
day
admiss
ci
day
fig
censor
patient
show
neg
rtpcr
result
consid
neg
viral
load
discharg
median
durat
viremia
ci
day
fig
addit
median
time
neg
rtpcr
result
sftsv
symptom
onset
ci
day
censor
patient
consid
neg
viral
load
discharg
median
durat
viremia
ci
day
supplement
fig
total
plasma
specimen
patient
sft
plasma
specimen
healthi
volunt
avail
cytokin
bead
array
analysi
gcsf
level
higher
sft
group
healthi
control
group
entir
cours
hospit
supplementari
fig
level
increas
earli
cours
diseas
decreas
late
cours
diseas
fig
contrast
concentr
rant
vegf
plasma
tend
increas
late
cours
diseas
fig
also
analyz
relationship
cytokin
chemokin
level
viral
rna
load
level
found
significantli
correl
viral
load
r
p
wherea
rant
vegf
show
invers
correl
viral
load
r
p
fig
detail
provid
supplementari
fig
viral
kinet
data
sft
patient
cours
diseas
essenti
understand
pathophysiolog
monitor
potenti
experiment
treatment
efficaci
predict
diseas
progress
transmiss
sft
howev
limit
data
detail
viral
kinet
patient
sft
yang
et
al
report
viral
load
reach
maximum
day
onset
symptom
gradual
decreas
neg
convers
rtpcr
half
patient
test
day
symptom
onset
wen
et
al
demonstr
sft
patient
review
sftsv
posit
accord
rtpcr
within
first
week
symptom
onset
current
data
show
median
time
neg
convers
rtpcr
result
sftsv
symptom
onset
day
slightli
differ
previou
studi
possibl
reason
discrep
may
methodolog
differ
realtim
rtpcr
anoth
possibl
explan
could
differ
sever
diseas
studi
studi
viral
load
kinet
stratifi
diseas
sever
minim
methodolog
variat
thu
need
among
cytokin
chemokin
test
present
analysi
level
plasma
specimen
highest
earli
cours
diseas
decreas
level
healthi
volunt
addit
sft
viral
load
posit
correl
level
invers
relationship
rant
vegf
virusinfect
cell
releas
type
ifn
caus
nearbi
cell
heighten
antivir
defens
addit
fact
ifnardefici
mice
highli
suscept
sftsv
suggest
import
resist
sftsv
infect
find
high
earli
stage
sft
consist
find
previou
studi
indic
might
involv
cytokin
storm
rather
control
sftsv
proinflammatori
cytokin
chemokin
elev
acut
phase
sft
support
cytokin
storm
theori
exhibit
suppress
effect
express
class
ii
major
histocompat
complex
costimulatori
molecul
surfac
monocyt
macrophag
result
inhibit
proinflammatori
cytokin
releas
variou
infect
howev
may
play
import
role
amplif
humor
respons
induc
activ
b
cell
secret
larg
amount
igg
iga
igm
previou
studi
viral
hemorrhag
fever
report
level
significantli
increas
acut
phase
crimeancongo
hemorrhag
fever
ebola
dengu
fever
addit
previou
studi
sft
demonstr
increas
sft
patient
therefor
consist
find
high
level
acut
stage
viral
hemorrhag
fever
highlight
import
balanc
cell
inhibit
b
cell
activ
therefor
studi
need
area
current
studi
level
decreas
level
elev
late
cours
diseas
repres
cytokin
subset
addit
found
vegf
releas
activ
platelet
tumor
cell
increas
late
stage
sft
studi
acut
bunyaviru
infect
hantaviru
crimeancongo
hemorrhag
fever
viru
report
bind
vegf
receptor
contribut
vascular
hyperperm
result
effus
interestingli
also
detect
increas
rant
level
late
stage
sft
reminisc
previou
studi
report
mark
elev
also
late
stage
survivor
middl
east
respiratori
syndrom
mer
previou
studi
similarli
report
increas
concentr
rant
survivor
ebola
viral
diseas
rant
recruit
activ
cell
cell
activ
may
play
import
role
recoveri
ebola
mer
sft
compar
concentr
cytokin
plasma
viral
rna
titer
posit
correl
cours
diseas
level
cytokin
viral
concentr
correl
day
admiss
correl
maintain
viral
rna
detect
disappear
viru
becam
undetect
suggest
sftsv
infect
induc
express
inflammatori
cytokin
find
consist
previou
report
show
concentr
correl
viral
load
sftsv
howev
plasma
level
patient
sft
vari
among
studi
two
report
level
sft
patient
higher
healthi
control
show
higher
concentr
sever
case
compar
nonsever
case
hand
studi
report
signific
differ
concentr
plasma
sampl
sever
nonsever
case
therefor
studi
need
understand
relationship
among
viral
load
diseas
sever
variou
cytokin
patient
sft
note
sever
limit
current
studi
first
one
nonsurvivor
thu
possibl
identifi
prognost
factor
associ
mortal
second
examin
respons
antibodi
cell
investig
adapt
immun
respons
sftsv
might
help
measur
titer
neutral
function
sftsvspecif
antibodi
identifi
profil
immun
cell
cours
infect
conclus
data
kinet
cytokin
plasma
patient
sft
might
provid
us
insight
pathogenesi
sft
viral
shed
kinet
blood
patient
sft
might
provid
guidanc
durat
treatment
isol
potenti
conflict
interest
author
